<img src="https://secure.leadforensics.com/133892.png" alt="" style="display:none;">

With an organic growth of 5% in Q3 and EBITDA growth of 48% in Q3 YTD, Columbus delivers a satisfactory result for the first 9 months, thus maintaining the expectations for the year.

Ballerup, 6 November 2019: Columbus closes the third quarter of the year with 5% organic growth on top of a satisfactory result for the first 9 months of the year The Group delivered a revenue of DKK 1.4bn in Q3 YTD, corresponding to an organic growth of 3% while EBITDA increased to DKK 165m, a growth of 48%.

Growth across business units
Columbus delivers growth across business areas, where especially cloud, Commerce, M3 and Columbus Care showed strong progress with double-digit growth. In Q3 isolated almost all business units delivered organic growth, where especially the business units Commerce and M3 showed strong progress with 17% and 18% growth.  

"I am very satisfied with the announced results, as we have delivered organic growth and strong EBITDA growth. Overall, we see strong growth across our business units and in our new business areas within the 9 Doors to Digital Leadership® with new growth opportunities for us to pursue”, says CEO & President in Columbus, Thomas Honoré.

Growth in new business areas
The sale of new business areas continues to deliver progress, where especially Analytics & Business Insight and Customer Experience show great growth numbers. During Q3, Columbus launched more services addressing industry-specific business pain points.

The 9 Doors to Digital Leadership® means that Columbus can deliver end-to-end digital solutions which helps customers maximize, transform and future-proof the business digitally.

Maintains expectations to 2019
Columbus maintains the announced expectations to 2019 with a revenue in the level of DKK 2bn and EBITDA in the level of DKK 240m.


For further information, please contact.
Communications Director
Tine Rasmussen
+45 29 69 06 77

9 doors


Discuss this post

Recommended posts

Minneapolis, Minn. (July 9, 2020): Columbus U.S. has announced a partnership with orthopedic medical device contract manufacturer Mach Medical. Using Microsoft technology, the Columbus U.S. team will help Mach Medical as they revolutionize the orthopedic supply chain by creating a manufacturing organization capable of building the highest quality joint replacement implants from a patient’s pre-operative surgical plan and supplying that product in time for surgery. Mach Medical’s proprietary high velocity, single-piece flow manufacturing approach is designed to reduce OEM implant inventory levels by 80%, trim per-part manufacturing costs by 30%, and cut new product time-to-market by 1-2 years.
Columbus continued the positive development from 2019 with revenue growth in the first two months of the year until COVID-19 hit the world community. Columbus is fully focused on serving customers digitally, adapting the business to the new situation and launching new digital sales and marketing initiatives to increase sales.
2019 was a good year for Columbus with 4% organic growth and EBITDA growth of 39%. The positive development continued in the first two months of the year, after which COVID-19 changed the conditions for 2020. Columbus is fully focused on serving customers and adapting the business to the changing situation.
With an EBITDA growth of 7%, Columbus delivers a satisfactory first half of 2019, and maintains full year expectations.
Columbus has appointed Chris Alagna as CEO of its US business
right-arrow share search phone phone-filled menu filter envelope envelope-filled close checkmark caret-down arrow-up arrow-right arrow-left arrow-down